期刊文献+

表观遗传学在糖尿病血管病变中的研究进展 被引量:3

Progress in epigenetics research in diabetic vascular diseases
原文传递
导出
摘要 表观遗传学(epigenetics)这一概念最早在1942年由Waddington提出,是指在DNA序列不发生变化但基因表达的水平和功能却发生了可遗传的改变,主要包括DNA甲基化、组蛋白共价修饰、微小RNA干扰等。这种控制机制的基因型未变而表型改变,并在细胞的分裂、增殖及之后的发育过程中都能稳定地传递下去,因而可引起相应的病理生理变化,从而与肿瘤、免疫、心血管、代谢综合征等多种疾病的发生发展有关。糖尿病是世界第三大慢性疾病,严重危害着人类健康,特别是糖尿病血管病变,即使血糖控制在理想状态下,其血管炎症仍能持续发生,提示存在“代谢记忆”,有研究指出可从表观遗传学水平阐明其发病机制。本文重点讨论DNA甲基化和组蛋白修饰,并就表观遗传学在糖尿病血管病变中的研究进展进行综述。 The concept of epigenetics was first proposed by Waddington in 1942, referring to phenotypic changes that are not related to the underlying DNA sequence, yet alterations in the level and function of gene expression can be heritable, such as DNA methylation, histone modifications, microRNA interference, etc. Phenotype changes while genotype remains unchanged, this controlled mechanism can be kept stable throughout cell division, proliferation, and subsequent process of development. This process thus may cause corresponding changes in the pathophysiology, which are correlated with the occurrence of cancer, immune disorder, cardiovascular disease, metabolic syndrome and so on. Diabetes mellitus is the third heaviest chronic diseases in the world, and does serious harm to human health, especially the diabetic vascular diseases. Even if the blood glucose level is controlled in an ideal state, vascular inflammation still persists, indicating the existence of metabolic memory. Studies have suggested that the pathogenesis can be elucidated at the level of epigenetics. This paper mainly focuses on DNA methylation, histone modifications, and is an overview of epigenetics research progress in diabetic vascular diseases.
出处 《中华内分泌代谢杂志》 CAS CSCD 北大核心 2013年第2期180-184,共5页 Chinese Journal of Endocrinology and Metabolism
基金 国家自然科学基金面上项目(31171129) 上海市科委科技发展基金基础研究重点课题(10JC1404800)
关键词 表观遗传学 糖尿病血管病变 代谢记忆 Epigenetics Diabetic vascular diseases Metabolic memory
  • 相关文献

参考文献5

二级参考文献93

  • 1王秀奇,李大海,何忠效.模板甲基化水平对鼠肝RNA聚合酶体外转录活性的影响[J].北京师范大学学报(自然科学版),1994,30(2):263-266. 被引量:5
  • 2姚煜,田涛,南克俊.白藜芦醇抗衰老免疫机制的研究[J].中药材,2006,29(5):464-467. 被引量:19
  • 3萨姆布鲁克 弗里奇.分子克隆实验指南[M].北京:科学出版社,1992(第2版).956-957.
  • 4Wynn TA.T(H)-17:a giant stepfrom T(H)1 andT(H)2.Nat Immunol,2005,6:1069-1070.
  • 5Kolls JK,Lindén A.Intedeukin-17 family members and inflammation.Immunity,2004,21:467-476.
  • 6Vukkedapu SS,Belli JM,Ishii K,et al.Dynamic interaction between T cell-mediated β-cell damage and β-cell repair in the run up to uutoimmune diabetes of the NOD mouse.Physiol Genomics,2005,21:201-211.
  • 7Haskins K,Portas M,Bergman B,et al.Pancreatic islet-specific T-cell clones from nonobese diabetic mice.Proc Natl Acad Sci,1989,86:8000-8004.
  • 8Turley S,Poirot L,Hattori M,et al.Physiological β cell death triggers priming of serf-reactive T cells by dendritic cells in a type-1 diabetes model.J Exp Med,2003,198:1527-1537.
  • 9Miljkovic D,Cvetkovic I,Momcilovic M,et al.Interleukin-17 stimulates inducible nitric oxide synthase-dependent toxicity in mouse beta cells.Cell Mol Life Sci,2005,62:2658-2668.
  • 10Aggarwal S,Gurney AL.IL-17:prototype member of an emerging cytokine family.J Leukoc Biol,2002,71:1-8.

共引文献22

同被引文献59

  • 1魏亚宁,舒青,张素珍.动脉粥样硬化AR基因甲基化修饰的初步探讨[J].第四军医大学学报,2004,25(15):1407-1409. 被引量:6
  • 2Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17- producing CD4+ effector T cells develop via a lineage distinct from the T helper type I and 2 lineages. Nat hnmunol, 2005,6 : 1123-1132.
  • 3Martel-Pelletier J, Mineau F, Jovanovic D, et al. Mitogenactivated protein kinase and nuclear factor kappaB together regulate interleukin- 17-induced nitric oxide production in human osteoarthritic chondrocytes: possible role of transactivating factor mitogen-activated protein kinase-activated proten kinase ( MAPKAPK). Arthritis Rheum, 1999,42:2399-2409.
  • 4Venkatachalam K, Mummidi S, Cortez DM, et al. Resveratrol inhibits high glucose-induced PI3K/Akt/ERK-dependent interleukin-17 expression in primary mouse cardiac fibroblasts. Am J Physiol Heart Circ Physiol, 2008,294 : H2078-H2087.
  • 5Patel DN, King CA, Bailey SR, et al. Interleukin-17 stimulates C- reactive protein expression in hcpatocytcs and smooth muscle cells via p38 MAPK and ERKl/2-dependent NF-kappaB and C/EBPbeta activation. J Biol Chem, 2007,282:27229-27238.
  • 6Broxmeyer HE. Is interleukin 17, an inducible cytokine that stimulates production of other cytokines, merely a redundant player in a sea of other biomolecules? J Exp Med, 1996,183:2411-2415.
  • 7Vukkadapu SS, Belli JM, lshii K, et al. Dynamic interaction between T cell-mediated beta-cell damage and beta-cell repair in the run up to autoimmune diabetes of the NOD mouse. Physiol Genomics, 2005,21 : 201-211.
  • 8Miljkovic D, Cvetkovic I, Momcilovic M, et al. Interleukin-17 stimulates inducible nitric oxide synthase-dependent toxicity in mouse beta cells. Cell Mol Life Sci, 2005,62:2658-2668.
  • 9Cheng G, Wei L, Xiurong W, et al. IL-17 stimulates migration of carotid artery vascular smooth muscle cells in an MMP-9 dependent manner via p38 MAPK and ERK1/2-dependent NF-kappaB and AP-I activation. Cell Mol Neurobiol, 2009,29 : 1161-1618.
  • 10Eid RE, Rao DA, Zhou J, et al. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle ceils. Circulation, 2009,119 : 1424-1432.

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部